REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend ...
RxPreferred's inclusion of YUSIMRY™ will have a significant impact on employer-sponsored health plans and their members with the biosimilar representing a 92% discount from the list price for Humira®.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback